Interim Analysis of a Study Exploring Indoximod/Pembrolizumab Combo in Melanoma

Video

Yousef Zakharia, MD, assistant professor, University of Iowa, Holden Comprehensive Cancer Center, discusses an interim analysis of the phase II clinical trial investigating the IDO pathway inhibitor indoximod in combination with pembrolizumab (Keytruda) for patients with advanced melanoma. 

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Elmariah on the Evolving Role of Fedratinib
Elmariah on the Evolving Role of Fedratinib
Clinical Evaluation of TMLI and PTCy in MRD-Negative AML Transplant
Clinical Evaluation of TMLI and PTCy in MRD-Negative AML Transplant
The Potential of Combination Therapy With Radiopharmaceuticals in Prostate Cancer
The Potential of Combination Therapy With Radiopharmaceuticals in Prostate Cancer
Exploring the Challenges of Radiopharmaceuticals in Prostate Cancer
Exploring the Challenges of Radiopharmaceuticals in Prostate Cancer
Lenvatinib as a Key First-Line Therapy in RAI-Refractory DTC
Lenvatinib as a Key First-Line Therapy in RAI-Refractory DTC
Elmariah on Maintenance Therapy Posttransplant for Myelofibrosis Relapse and GVHD Prevention
Elmariah on Maintenance Therapy Posttransplant for Myelofibrosis Relapse and GVHD Prevention
Fedratinib Shows Promise in Long-Term MPN Success With Tolerable Toxicity
Fedratinib Shows Promise in Long-Term MPN Success With Tolerable Toxicity
Auletta Delves Into the ACCESS Trial and GVHD Prevention
Auletta Delves Into the ACCESS Trial and GVHD Prevention
Real-World Bispecific Antibody Use Post-CAR T in DLBCL
Real-World Bispecific Antibody Use Post-CAR T in DLBCL
Behind the Phase 3 3475A-D77 Trial of SC Pembrolizumab in NSCLC
Behind the Phase 3 3475A-D77 Trial of SC Pembrolizumab in NSCLC
Related Content
Improving Quality of Life in LR-MDS Through Anemia Treatment

Improving Quality of Life in LR-MDS Through Anemia Treatment

Targeted Oncology Staff
April 18th 2025
Article

During a live event, Chris Benton, MD, discussed the focus on anemia management, reducing transfusions, and improving quality of life in MDS.

Read More

Advancing Melanoma Treatment: Hamid on Lifileucel's Role

Advancing Melanoma Treatment: Hamid on Lifileucel's Role

Jordyn Sava;Omid Hamid, MD
July 15th 2024
Podcast

In this episode of Targeted Talks, Omid Hamid, MD, discusses data supporting the use of lifileucel for the treatment of advanced melanoma.

Listen

Novel Radioenhancer JNJ-1900 Shows Potential Across Cancers

Novel Radioenhancer JNJ-1900 Shows Potential Across Cancers

Jordyn Sava
April 15th 2025
Article

Jared Weiss, MD, discussed the mechanism of action of JNJ-1900 and the preliminary data presented at the 2025 European Lung Cancer Congress.

Read More

Understanding and Treating Mucosal Melanoma

Understanding and Treating Mucosal Melanoma

Nichole Tucker;Richard Carvajal, MD
April 14th 2023
Podcast

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

Listen

FDA Backs Darovasertib Phase 3 Trial Design in Uveal Melanoma

FDA Backs Darovasertib Phase 3 Trial Design in Uveal Melanoma

Jordyn Sava
April 14th 2025
Article

Following a recent Type D meeting with the FDA, a phase 3 clinical trial design for darovasertib in primary uveal melanoma has been announced.

Read More

First Patient Receives KSQ-004EX for Advanced Cancer

First Patient Receives KSQ-004EX for Advanced Cancer

Jordyn Sava
April 12th 2025
Article

A phase 1/2 trial of CRISPR-engineered eTIL therapy KSQ-004EX for advanced solid tumors has dosed its first patient.

Read More